Heterologous effects
Showing 1 - 25 of 359
Trained and Heterologous Induced-immune Responses to Tropical
Not yet recruiting
- Tropical Infectious Disease
- Diagnostic tests
- Equilibrate diet
- (no location specified)
Feb 8, 2023
COVID-19 Trial in Bandung (SARS-CoV-2 subunit protein recombinant vaccine)
Not yet recruiting
- COVID-19
- SARS-CoV-2 subunit protein recombinant vaccine
-
Bandung, Jawa Barat, IndonesiaFaculty of Medicine Universitas Padjadjaran
Feb 13, 2023
COVID-19 Trial in Chengdu (LYB002V14, LYB002V14A, LYB002CA)
Active, not recruiting
- COVID-19
- LYB002V14
- +2 more
-
Chengdu, Sichuan, ChinaAffiliated Hospital of North Sichuan MedicalCollege
Jun 29, 2023
COVID-19, Vaccine Reaction Trial in Chengdu (LYB001, CoronaVac)
Active, not recruiting
- COVID-19
- Vaccine Reaction
- LYB001
- CoronaVac
-
Chengdu, Sichuan, ChinaChengdu Xinhua Hospital Affiliated to North Sichuan Medical Coll
Jun 29, 2023
Chronic Hepatitis B Trial in Hamburg (HEPLISAV B; TherVacB, TherVacB)
Not yet recruiting
- Chronic Hepatitis B
- HEPLISAV B; TherVacB
- TherVacB
-
Hamburg, GermanyCTC North
Feb 3, 2023
Healthy Adult Volunteers Trial in Taipei City (ChAdOx1-nCov-19 (Astra-Zeneca), SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine)
Completed
- Healthy Adult Volunteers
- ChAdOx1-nCov-19 (Astra-Zeneca)
- SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
-
Taipei City, X, TaiwanNational Taiwan University Hospital
Oct 16, 2022
COVID-19 Trial in Bizerte, Ariana, Tunis (CoronaVac/CoronaVac, CoronaVac/BNT162b2)
Completed
- COVID-19
- CoronaVac/CoronaVac
- CoronaVac/BNT162b2
-
Bizerte, Mateur, Tunisia
- +4 more
Jan 4, 2023
COVID-19 Trial in Al Ain (AZD1222, rAd26-S)
Completed
- COVID-19
- AZD1222
- rAd26-S
-
Al Ain, United Arab EmiratesTawam Hospital
Oct 24, 2022
Malaria, Malaria,Falciparum Trial in Baltimore (PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline)
Recruiting
- Malaria
- Malaria,Falciparum
- PfSPZ Vaccine
- +2 more
-
Baltimore, MarylandUniversity of Maryland, Baltimore, Center for Vaccine Developmen
Nov 2, 2022
Ebola Virus Disease Trial in Boende (Ad26.ZEBOV vaccine)
Completed
- Ebola Virus Disease
- Ad26.ZEBOV vaccine
-
Boende, Province De La Tshuapa, Congo, The Democratic Republic of theHôpital Général de Référence de Boende
Jan 3, 2023
COVID-19, Breakthrough Infection Trial in Taoyuan city (BNT162b2, mRNA-1273, MVC-COV1901)
Active, not recruiting
- COVID-19
- Breakthrough Infection
- BNT162b2
- +2 more
-
Taoyuan city, TaiwanChang Gung Memorial Hospital
Jul 21, 2022
SARS-CoV-2 Trial in Islamabad (LVRNA009, CoronaVac®)
Not yet recruiting
- SARS-CoV-2
- LVRNA009
- CoronaVac®
-
Islamabad, PakistanClinical Trial Unit, National Institute of Health
Jun 22, 2022
COVID-19 Trial (GBP510 adjuvanted with AS03, Placebo (Normal Saline))
Not yet recruiting
- COVID-19
- GBP510 adjuvanted with AS03
- Placebo (Normal Saline)
- (no location specified)
Aug 11, 2022
Malaria Trial in Seattle (PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline)
Completed
- Malaria
- PfSPZ Vaccine
- +2 more
-
Seattle, WashingtonFred Hutchinson Cancer Research Center
Jul 15, 2022
COVID-19 Trial in Nanjing (Ad5-nCoV-IH, Ad5-nCoV-IM, CoronaVac)
Active, not recruiting
- COVID-19
- Ad5-nCoV-IH
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Diseases Control and Prevention
Aug 12, 2022
COVID-19 Trial (UB-612)
Withdrawn
- COVID-19
- UB-612
- (no location specified)
Feb 13, 2022
SARS-CoV-2, Safety, Immunotoxicity Trial in Wuhan (one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006), Cellular Immunity,
Not yet recruiting
- SARS-CoV-2
- +2 more
- one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
- +3 more
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Aug 9, 2022
Covid19 Vaccine Trial in Taipei (Homologous boost schedule, Heterologous boost schedule)
Active, not recruiting
- Covid19 Vaccine
- Homologous boost schedule
- Heterologous boost schedule
-
Taipei, TaiwanNational Taiwan University Hospital
Nov 28, 2021
COVID-19 Vaccines Trial in Panama, Philippines, United States (UB-612, BNT162b2 vaccine, ChAdOx1-S vaccine)
Active, not recruiting
- COVID-19 Vaccines
- UB-612
- +3 more
-
Brownsville, Texas
- +6 more
Oct 11, 2022
Covid-19, Vaccine, Immunogenicity Trial in Taoyuan (Heterologous prime-boost schedule with AZD1222 and MVC-COV1901, Homologous
Recruiting
- Covid-19
- +4 more
- Heterologous prime-boost schedule with AZD1222 and MVC-COV1901
- Homologous prime-boost schedule with two doses of AZD1222
-
Taoyuan, TaiwanChangGungMH
Oct 19, 2021
SARS-CoV-2 Infection Trial in Bangkok (Full dose of Ad26.COV2. 5x10^10vp, Half dose of Ad26.COV2. 2.5x10^10vp)
Recruiting
- SARS-CoV-2 Infection
- Full dose of Ad26.COV2. 5x10^10vp
- Half dose of Ad26.COV2. 2.5x10^10vp
-
Bangkok, ThailandVaccine Trial Centre, Faculty of Tropical Medicine, Mahidol Univ
Sep 11, 2022
COVID-19 Trial in Cali (VLA 2001)
Not yet recruiting
- COVID-19
- VLA 2001
-
Cali, Valle, ColombiaCentro de Estudios en Infectología Pediátrica
Sep 15, 2022
COVID-19 Trial in Nanjing (recombinant Ad5 vectored COVID-19 vaccine, RBD-based protein subunit vaccine (ZF2001) against
Completed
- COVID-19
- recombinant Ad5 vectored COVID-19 vaccine
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Diseases Control and Prevention
Mar 28, 2022
COVID-19 Trial in Singapore (Homologous mRNA booster vaccine, Heterologous mRNA booster vaccine, Non-mRNA booster vaccine A)
Recruiting
- COVID-19
- Homologous mRNA booster vaccine
- +4 more
-
Singapore, SingaporeNational Centre for Infectious Diseases (NCID)
Nov 30, 2021
COVID-19 Pandemic Trial (Lyophilized COVID-19 mRNA Vaccine, Sodium chloride)
Not yet recruiting
- COVID-19 Pandemic
- Lyophilized COVID-19 mRNA Vaccine
- Sodium chloride
- (no location specified)
Nov 18, 2022